<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05614869</url>
  </required_header>
  <id_info>
    <org_study_id>EM-05-014992</org_study_id>
    <nct_id>NCT05614869</nct_id>
  </id_info>
  <brief_title>Continuous Treatment With PREVENA Therapy for 14 Days</brief_title>
  <official_title>A Prospective, Single-arm, Multi-center, Open-label Trial Evaluating the Continuous Application of Prevena™ Therapy for up to 14 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>3M</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>3M</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety and effectiveness of Prevena Therapy&#xD;
      for up to 14 days is comparable to the current approved use for up to 7 days. The enrolled&#xD;
      subject will undergo 1 of 4 surgery types and be evaluated for up to 90 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2023</start_date>
  <completion_date type="Anticipated">May 25, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint</measure>
    <time_frame>30 Days</time_frame>
    <description>The incidence of surgical site complications (SSCs), including surgical site infections (SSIs) and seromas, within 30 days (± 4 days) of the surgical procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical Site Complications_30</measure>
    <time_frame>30 Days</time_frame>
    <description>The number and type of SSCs within 30 days (± 4 days) of the surgical procedure, including SSI, seroma, hematoma, dehiscence, and skin necrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Site Complications_90</measure>
    <time_frame>90 Days</time_frame>
    <description>The number and type of SSCs within 90 days (± 7 days) of the surgical procedure, including SSI, seroma, hematoma, dehiscence, and skin necrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Site Infections</measure>
    <time_frame>30 Days</time_frame>
    <description>The incidence of SSI (superficial or deep) within 30 days (± 4 days) of the surgical procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroma</measure>
    <time_frame>30 Days</time_frame>
    <description>The incidence of seroma within 30 days (± 4 days) of the surgical procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematoma</measure>
    <time_frame>30 Days</time_frame>
    <description>The incidence of hematoma within 30 days (± 4 days) of the surgical procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dehiscence</measure>
    <time_frame>30 Days</time_frame>
    <description>The incidence of dehiscence within 30 days (± 4 days) of the surgical procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Necrosis</measure>
    <time_frame>30 Days</time_frame>
    <description>The incidence of skin necrosis within 30 days (± 4 days) of the surgical procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Abdominal Surgery</condition>
  <condition>Orthopedic Surgery</condition>
  <condition>Cardiovascular Surgery</condition>
  <condition>Vascular Surgery</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects undergoing 1 of 4 types of surgery will be enrolled and treated with the PREVENA Plus Incision Management System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prevena Plus Incision Management System with Prevena Dressings</intervention_name>
    <description>Negative pressure pump and dressings</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is at least 22 years of age on the date of informed consent&#xD;
&#xD;
          -  Subject can provide informed consent&#xD;
&#xD;
          -  Subject requires a surgical procedure for 1 of the 4 specialty treatment groups (ie,&#xD;
             lower extremity orthopedic procedure, abdominal or C-section procedure, sternotomy, or&#xD;
             vascular procedure)&#xD;
&#xD;
          -  Subject is willing and able to return for all scheduled study visits.&#xD;
&#xD;
          -  Subject has 1 or more of the following risk factors for post-surgical complications:&#xD;
&#xD;
               -  BMI ≥ 30&#xD;
&#xD;
               -  diabetes&#xD;
&#xD;
               -  history of smoking&#xD;
&#xD;
               -  immune suppression or receiving drugs that can cause immune suppression (eg,&#xD;
                  steroids, chemotherapeutic medications, and/or antimetabolites)&#xD;
&#xD;
               -  high risk for malnutrition, as indicated by 2 or more of the following1:&#xD;
&#xD;
                    -  insufficient energy intake&#xD;
&#xD;
                    -  loss of muscle mass&#xD;
&#xD;
                    -  loss of subcutaneous fat&#xD;
&#xD;
                    -  localized or generalized fluid accumulation that may mask weight loss&#xD;
&#xD;
                    -  diminished functional status as measured by hand-grip strength&#xD;
&#xD;
          -  OR -&#xD;
&#xD;
               -  has malnutrition, as determined by the investigator&#xD;
&#xD;
                    -  neutropenia&#xD;
&#xD;
                    -  cardiac, pulmonary, liver, or renal disease&#xD;
&#xD;
                    -  history of previous surgery or radiation in the treatment area&#xD;
&#xD;
          -  Subject is pre-operatively assessed to undergo a procedure with a CDC Wound&#xD;
             Classification of:&#xD;
&#xD;
               -  Class I (Clean): An uninfected operative wound in which no inflammation is&#xD;
                  encountered, and the respiratory, alimentary, genital, or uninfected urinary&#xD;
                  tract is not entered&#xD;
&#xD;
          -  OR -&#xD;
&#xD;
               -  Class II (Clean Contaminated): An operative wound in which the respiratory,&#xD;
                  alimentary, genital, or uninfected urinary tract are entered under controlled&#xD;
                  conditions and without unusual contamination&#xD;
&#xD;
          -  Subject has a closed post-surgical incision for which the anticipated duration of&#xD;
             Prevena Therapy is more than 11 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is female and, except in the case of C-section procedures, is pregnant or&#xD;
             lactating prior to surgery&#xD;
&#xD;
          -  Subject has signs of an infection in the surgical area or has signs of a systemic&#xD;
             infection at the time of surgery&#xD;
&#xD;
          -  Subject is a chronic opioid user, defined per the CDC guidelines as opioid use for &gt; 3&#xD;
             months, at the time of enrollment&#xD;
&#xD;
          -  Subject has any of the following:&#xD;
&#xD;
               -  condition(s) that, in the opinion of the investigator, cause the patient to be an&#xD;
                  overall health risk that is unsuitable for the surgery&#xD;
&#xD;
               -  known sensitivity to the study product components (drape and/or dressing&#xD;
                  materials in direct contact with the closed incision or skin)&#xD;
&#xD;
               -  known sensitivity to silver&#xD;
&#xD;
               -  skin cancer localized at or in proximity to the incision site&#xD;
&#xD;
               -  intraoperative issue(s) that precludes the use of Prevena Therapy&#xD;
&#xD;
          -  Subject is preoperatively assessed to undergo a procedure with a CDC Wound&#xD;
             Classification of:&#xD;
&#xD;
               -  Class III (Contaminated): Open, fresh, accidental wounds, and/or major breaks in&#xD;
                  sterile technique or gross spillage from the gastrointestinal tract&#xD;
&#xD;
          -  OR -&#xD;
&#xD;
               -  Class IV (Dirty-Infected): Old traumatic wounds with retained devitalized tissue&#xD;
                  and those that involve existing clinical infection or perforated viscera&#xD;
&#xD;
          -  Subject is enrolled in another interventional clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Synatschk, MS, CCRP</last_name>
    <phone>346-550-5698</phone>
    <email>esynatschk@mmm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taj-Jamal Andrews, MD, MBA</last_name>
      <email>tandrews@lifebridgehealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Aja Janyavula</last_name>
      <email>ajanyavula@lifebridgehealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jo Anne Goldman</last_name>
      <email>Joanne.goldman@allina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>WakeMed Heart &amp; Vascular</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rhonda Norton, CCRC</last_name>
      <email>rnorton@wakemed.org</email>
    </contact>
    <contact_backup>
      <last_name>Taylor Guidi</last_name>
      <email>tguidi@wakemed.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Behrens</last_name>
      <email>behrensh@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Morgan Overstreet</last_name>
      <email>overstrm@musc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.acelity.com/healthcare-professionals/global-product-catalog/catalog/prevena-incision-management-system</url>
    <description>Study Product Information</description>
  </link>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>April 6, 2023</last_update_submitted>
  <last_update_submitted_qc>April 6, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Median Sternotomy</keyword>
  <keyword>Total Hip Replacement</keyword>
  <keyword>Total Knee Replacement</keyword>
  <keyword>Groin Surgery</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

